Overes et al. [57] demonstrated that P2X5-expressing lymphoid tumor cells were recognized and lysed by LRH-1-specific cytotoxic T lymphocytes, suggesting that P2X5 might represent a promising target for immunotherapy. Here, P2RX5 is linked to lymphoid neoplasm.